Rosiglitazone prevents the memory deficits induced by amyloid-beta oligomers via inhibition of inflammatory responses

Neuroscience Letters

Volumn 578, Issue , 2014, Pages 7-11

  Xu, Shujun ^a   Guan, Qiao ^a   Wang, Chuang ^a   Wei, Xiaofei ^a   Chen, Xiaowei ^a   Zheng, Bangxu ^a   An, Pengyuan ^a   Zhang, Junfang ^a   Chang, Lan ^a   Zhou, Wenhua ^a   Mody, Istvan ^a   Wang, Qinwen ^a  

^a NINGBO UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Amyloid beta 42 oligomers; Inflammatory cytokines; Long term potentiation; Rosiglitazone

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1BETA; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); AUTACOID; NEUROPROTECTIVE AGENT; PEPTIDE FRAGMENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ELECTROPHYSIOLOGY; BRAIN LEVEL; BRAIN SLICE; CELL ACTIVATION; CONTROLLED STUDY; DENTATE GYRUS; DOSE RESPONSE; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HIPPOCAMPUS; INFLAMMATION; LONG TERM POTENTIATION; MALE; MEMORY DISORDER; MICROGLIA; MORRIS WATER MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; COGNITION DISORDERS; DRUG EFFECTS; MAZE TEST; MEMORY DISORDERS; METABOLISM; MOTOR ACTIVITY; PHYSIOLOGY; WISTAR RAT;

AMYLOID BETA-PEPTIDES; ANIMALS; COGNITION DISORDERS; HIPPOCAMPUS; INFLAMMATION MEDIATORS; INTERFERON-GAMMA; INTERLEUKIN-1BETA; LONG-TERM POTENTIATION; MALE; MAZE LEARNING; MEMORY DISORDERS; MICROGLIA; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; RATS; RATS, WISTAR; THIAZOLIDINEDIONES;

EID: 84903842921     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2014.06.010     Document Type: Article

References (21)

1. Cleary J.P., Walsh D.M., Hofmeister J.J., Shankar G.M., Kuskowski M.A., Selkoe D.J., Ashe K.H. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 2005, 8:79-84.
2. Denner L.A., Rodriguez-Rivera J., Haidacher S.J., Jahrling J.B., Carmical J.R., Hernandez C.M., Zhao Y., Sadygov R.G., Starkey J.M., Spratt H., Luxon B.A., Wood T.G., Dineley K.T. Cognitive enhancement with rosiglitazone links the hippocampal PPAR and ERK MAPK signaling pathways. J. Neurosci. 2012, 32:16725-16735.
3. Dickson D.W. Neuropathological diagnosis of Alzheimer's disease: a perspective from longitudinal clinicopathological studies. Neurobiol. Aging 1997, 18:S21-S26.
4. Gold M., Alderton C., Zvartau-Hind M., Egginton S., Saunders A.M., Irizarry M., Craft S., Landreth G., Linnamagi U., Sawchak S. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement. Geriatr. Cogn. Disord. 2010, 30:131-146.
5. Hein A.M., Stasko M.R., Matousek S.B., Scott-McKean J.J., Maier S.F., Olschowka J.A., Costa A.C., O'Banion M.K. Sustained hippocampal IL-1beta overexpression impairs contextual and spatial memory in transgenic mice. Brain Behav. Immun. 2010, 24:243-253.
6. Kapadia R., Yi J.H., Vemuganti R. Mechanism of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front. Biosci. 2008, 13:1813-1826.
7. Loane D.J., Deighan B.F., Clarke R.M., Griffin R.J., Lynch A.M., Lynch M.A. Interleukin-4 mediates the neuroprotective effects of rosiglitazone in the aged brain. Neurobiol. Aging 2009, 30:920-931.
8. Luconi M., Cantini G., Serio M. Peroxisome proliferator-activated receptor gamma (PPARgamma): is the genomic activity the only answer. Steroids 2010, 75:585-594.
9. McGeer P.L., McGeer E.G. Inflammation and the degenerative diseases of aging. Ann. N.Y. Acad. Sci. 2004, 1035:104-116.
10. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods 1984, 11:47-60.
11. Ojala J., Alafuzoff I., Herukka S.K., van Groen T., Tanila H., Pirttila T. Expression of interleukin-18 is increased in the brains of Alzheimer's disease patients. Neurobiol. Aging 2009, 30:198-209.
12. Parajuli B., Sonobe Y., Horiuchi H., Takeuchi H., Mizuno T., Suzumura A. Oligomeric amyloid β induces IL-1β processing via production of ROS: implication in Alzheimer's disease. Cell Death Dis. 2013, 4:e975.
13. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science 2002, 298:789-791.
14. Selkoe D.J. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav. Brain Res. 2008, 192:106-113.
15. Tam J.H., Pasternak S.H. Amyloid and Alzheimer's disease: inside and out. Can. J. Neurol. Sci. 2012, 39:286-298.
16. Toledo E.M., Inestrosa N.C. Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer's disease. Mol. Psychiatry 2010, 15(228):272-285.
17. Wang Q., Rowan M.J., Anwyl R. Beta-amyloid-mediated inhibition of NMDA receptor-dependent long-term potentiation induction involves activation of microglia and stimulation of inducible nitric oxide synthase and superoxide. J. Neurosci. 2004, 24:6049-6056.
18. Woster A.P., Combs C.K. Differential ability of PPAR gamma agonist to attenuate cytokine secretion in primary microglia and macrophage-like cells. J. Neurochem. 2007, 103:67-76.
19. Xu J., Drew P.D. Peroxisome proliferator-activated receptor-gamma agonists suppress the production of IL-12 family cytokines by activated glia. J. Immunol. 2007, 178:1904-1913.
20. Xu S., Liu G., Bao X., Wu J., Li S., Zheng B., Anwyl R., Wang Q. Rosiglitazone prevents amyloid-β oligomer-induced impairment of synapse formation and plasticity via increasing dendrite and spine mitochondrial number. J. Alzheimers Dis. 2014, 39:239-251.
21. Zhao W.Q., Townsend M. Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. Biochim. Biophys. Acta. 2009, 1792:482-496.